CAR T-Cell Therapy

In an interview with Targeted Oncology, Frederick L. Locke, MD, discussed how the elimination of the REMS program for CAR T-cell therapy came about and what effects he hopes this will have on patient access.

Community-based CAR T-cell therapy expands access to innovative cancer treatments, improving patient outcomes and reducing hospital stays for patients with blood cancers.

CAR T-cell therapy for DLBCL shows promise in outpatient settings, reducing hospital stays and improving patient quality of life while managing toxicities effectively.

Explore the complexities of CAR T-cell therapy, focusing on noncanonical toxicities like ICAHT and IEC-HS, and their management strategies.

Emerging CAR T-cell therapies, like DuoCAR20.19.22-D95, show promise in overcoming challenges in treating relapsed B-cell malignancies.

Brexu-cel demonstrated efficacy and safety even in patients with B-cell acute lymphoblastic leukemia with central nervous system involvement.

During a live event, Nathan Denlinger, DO, MS, discussed outcomes of the ZUMA-7 trial in diffuse large B-cell lymphoma.

During a live event, Jorge Monge, MD, discussed real-world evidence on the use of CAR T-cell therapy beyond the trial setting in multiple myeloma.

Allogene Therapeutics halts ALLO-647 trial in large B-cell lymphoma after a patient death raises safety concerns, impacting future research.

FDA prioritizes review of liso-cel, a groundbreaking CAR T-cell therapy for relapsed marginal zone lymphoma, promising improved patient outcomes.

FCARH143, a CAR T-cell therapy, delivered a 100% objective response rate in a phase 1 trial in patients with relapsed/refractory multiple myeloma.

During a live event, Matthew Lunning, DO, and participants discussed how identifying primary refractory and early relapsed DLBCL matters for using second-line CAR T-cell therapy.

During a live event, Jorge Monge, MD, discussed short and long-term adverse events associated with CAR T-cell therapy in multiple myeloma.

Allogeneic cell therapies are advancing in clinical trials, requiring oncologists and pathologists to understand the opportunities they present for patients and the potential challenges from a laboratory perspective.

FDA updates CAR T-cell therapy labels, easing monitoring requirements and expanding access for eligible patients in oncology.

A new platform comprehensively profiles CAR T-cells during manufacturing, revealing phenotypic shifts. This allows for shorter timelines, better outcomes, and personalized therapies.

Lisocabtagene maraleucel led to promising responses in relapsed/refractory marginal zone lymphoma, offering a new option with manageable safety.

During a live event, Konstantinos Sdrimas, MD, and community oncologists discussed patient concerns over CAR T-cell therapy toxicity and how to coordinate with CAR T providers.

During a live event, Samuel M. Rubinstein, MD, discussed the outcomes from the KarMMa-3 trial and real-world patients receiving ide-cel in terms of bridging therapy, quality of life, and prior BCMA therapy.

During a live event, Konstantinos Sdrimas, MD, asked participants what community oncologists should consider when referring patients for CAR T-cell therapy.

During a live event, Samuel M. Rubinstein, MD, discussed the efficacy and safety outcomes from the KarMMa-3 trial.

In separate live virtual events, Sarah A. Holstein, MD, PhD, and Shashank Cingam, MD, discuss options for a patient with relapsed/refractory multiple myeloma and the use of chimeric antigen receptor (CAR) T-cell therapy.

The AERIAL trial will assess LEU011, which has MHRA Innovation Passport status, for solid tumors, a challenging area compared with hematologic cancers.

Geoffrey Shouse, DO, PhD, discusses what motivated this retrospective review of bispecific antibodies in diffuse large B-cell lymphoma at City of Hope.

Frederick L. Locke, MD, discussed cema-cel's safety, efficacy, and potential for treating large B-cell lymphoma in earlier lines in the ALPHA trials.